Evidence map›Paper›PMID 24121068›Full record

ArticlePain2014

Characterization of a novel model of chronic migraine.

Amynah A Pradhan, Monique L Smith, Brenna McGuire, Igal Tarash, Christopher J Evans, Andrew Charles

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pain, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 201 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
201citing papers in PubMed, 2 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

201 citing papers in PubMed, 2 syntheses or guidelines pooled it, 345 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. PVNAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  14. The therapeutic pipeline in migraine: What does the future hold?Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

141 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Amynah A PradhanSemel Institute for Neuropsychiatry and Human Behavior, University of California, Los Angeles, USA Shirley and Stefan Hatos Center for Neuropharmacology, University of California, Los Angeles, USA Headache Research and Treatment Program, Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, USA Department of Psychiatry, University of Illinois at Chicago, USA.
Monique L Smith
Brenna McGuire
Igal Tarash
Christopher J Evans
Andrew Charles
University of California, Los Angeles · US

Funding

The Role of Striosome Neurons in Mediating Opiod RewardP50DA005010 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FANSELOW, MICHAEL S · 1987 to 2021
$30.7M
In Vivo Implications of Agonist Selective Activation of Delta Opioid ReceptorR00DA031243 · NIDA · UNIVERSITY OF ILLINOIS AT CHICAGO · PI PRADHAN, AMYNAH AMIR ALI · 2013 to 2015
$743k
In Vivo Implications of Agonist Selective Activation of Delta Opioid ReceptorK99DA031243 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PRADHAN, AMYNAH AMIR ALI · 2011 to 2012
$317k
NIDA NIH HHS DA031243NIDA NIH HHS DA05010NIDA NIH HHS K99 DA031243NIDA NIH HHS P50 DA005010NIDA NIH HHS R00 DA031243
6 · The paper itself

Abstract

Chronic migraine is a disabling condition that affects hundreds of millions of individuals worldwide. The development of novel migraine treatments has been slow, in part as a result of a lack of predicative animal models. We have developed a new model of chronic migraine involving the use of nitroglycerin (NTG), a known migraine trigger in humans. Chronic intermittent administration of NTG to mice resulted in acute mechanical hyperalgesia with each exposure as well as a progressive and sustained basal hyperalgesia. This chronic basal hyperalgesia occurred in a dose-dependent fashion and persisted for days after cessation of NTG administration. NTG-evoked hyperalgesia was exacerbated by the phosphodiesterase 5 inhibitor sildenafil, also a human migraine trigger, consistent with nitric oxide as a primary mediator of this hyperalgesia. The acute but not the chronic basal hyperalgesia was significantly reduced by the acute migraine therapy sumatriptan, whereas both the acute and chronic hyperalgesia was significantly attenuated by the migraine preventive therapy topiramate. Chronic NTG-induced hyperalgesia is a mouse model that may be useful for the study of mechanisms underlying progression of migraine from an episodic to a chronic disorder, and for the identification and characterization of novel acute and preventive migraine therapies.

Indexed as

Disease Models, AnimalAnimalsChronic DiseaseFemaleFreund's AdjuvantHyperalgesiaMaleMiceMice, Inbred C57BLMigraine DisordersNitroglycerinPain MeasurementSumatriptanVasodilator AgentsFreund's AdjuvantNitroglycerinSumatriptanVasodilator AgentsCentral sensitizationHeadacheHyperalgesia

Identifiers

PMID24121068
PMCPMC3920577
OpenAlexW2066749613

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.